ABSTRACT
Amisulpride is an atypical antipsychotic drug which differs pharmacologically from other atypical agents by virtue of its high selectivity for dopamine D2 and D3 receptors. The drug was first introduced into clinical practice as an antipsychotic in 1987 and has since been used extensively, with over 600 million patient treatment days recorded. Clinically, amisulpride is characterized by a low prevalence of extrapyramidal symptoms (EPS) and efficacy in relieving positive and negative symptoms of schizophrenia. As well as being a highly effective first-line treatment for acute psychotic episodes, amisulpride, when used at low doses, is possibly the best current maintenance treatment for chronically negative schizophrenic subjects.
